Alliance Pharma FY profits seen in line with expectations

Alliance Pharma
62.50p
17:00 27/02/25
International healthcare firm Alliance Pharma said on Friday that FY24 group profits would be in line with expectations despite a modest downturn in revenues.
FTSE AIM 100
3,410.68
16:54 27/02/25
FTSE AIM 50
3,730.71
16:54 27/02/25
FTSE AIM All-Share
707.72
16:54 27/02/25
Pharmaceuticals & Biotechnology
22,414.59
17:14 27/02/25
Alliance Pharma said it had delivered group see-through revenues of £180.3m in FY24, down 1% year-on-year, but noted that while revenues declined in some of its brands, it had delivered a "strong performance" in Kelo-Cote, MacuShield, Hydromol and Forceval.
Chief executive Nick Sedgwick said: " I am pleased that performance in 2024 is in-line with expectations. Whilst we have much to do as we work on our transformation plans, I am confident that our strong portfolio of clinically differentiated brands will deliver predictable organic revenue growth over the mid-long term."
As of 0930 GMT, Alliance Pharma shares were up 0.33% at 61.40p.
Reporting by Iain Gilbert at Sharecast.com